Osborne Clarke has advised some of the shareholders of Dynamic Biosensors GmbH, a company specialising in biosensor technology, on the sale to Bruker Corporation.
Munich-based Dynamic Biosensors GmbH is known for its innovative heliX biosensor series, which enables comprehensive biophysical characterisation of molecular interactions. The pioneer in biosensor development was founded in 2012 by Dr Frank Fischer, Wolfgang Kaiser, Dr Ulrich Rant, Dr Dirk Scholl and Dr Ralf Strasser as a spin-off from the Technical University of Munich and Fujitsu Ltd.
Bruker Corporation, an American manufacturer of scientific instruments for molecular and material research, has now acquired the company to expand its biophysical portfolio for the analysis of molecular interactions.
The parties have agreed to keep the purchase price and further details of the transaction confidential.
The Osborne Clarke team, led by Dr Martin Sundermann, that advised a part of the shareholders of Dynamic Biosensors, consisted of Dr. Felix Dörrenbächer (Senior Associate M&A/VC), Enno Dreier (Counsel M&A), Elisabeth Falterer (Senior Associate M&A), Florian Merkle (Counsel Tax), Patrick Seiler (Senior Associate Tax), Dr. Tim Reinhard (Partner IP), Konstantin Sitte (Counsel IP), Tamara Giebisch (Associate IP), Dr. Hendrik Schöttle (Partner IT), Dr. Florian Eisenmenger (Counsel IT) and Beata Regina Völker (Associate IT).
Corporate communications and press contacts
Connect with one of our experts
